29 Jun 2021
TFS & a Global Biotech Company
As clinical trials grow increasingly complex, timelines shorten, and R&D costs soar. Today’s
biopharmaceutical companies are under intense pressure. They need to not only improve efficiency
while managing costs, but also be able to flex up or down based on corporate priorities. A global
biotech company partnered with TFS in a Functional Service Provider (FSP) program that provides
a tailored solution to share complementary expertise for the long-term, while ensuring flexibility in
the short-term. Now, eleven years later, the partnership continues to thrive with a new contract signed
through 2022. Here’s how TFS made it happen.
After many years of working on an ad-hoc basis with TFS and other biopharmaceutical services
providers, this biotech client decided to move to an FSP model that would allow a deeper partnership
and more continuity of work. With an established relationship underpinned by a personal, tailored
approach, TFS was a natural choice for their FSP partner. But building the model would not be easy.
The client needed to fully erect the model in a tight window to ensure continuity of its programs. That
meant rapid, intensive training for the TFS CRAs, CTAs, line managers and trainers deployed across its
clinical trials. Given the diversity of the trials which spanned multiple therapeutic areas; hematology,
cardiovascular, oncology, inflammatory diseases amongst others, the team needed to have both
breadth and depth of knowledge to succeed.